Both Pfizer and GSK have shared preliminary data suggesting that their experimental vaccines can protect older adults and newborn infants from the virus.
In line with previous research, a new study in mice demonstrates that B cells can be engineered to ward off infections, this time against respiratory syncytial virus (RSV).